Diabetes

The No. 1 cause of death, cardiovascular disease, is preventable.

At some point in your career, you've probably encountered questions from patients or health care team members about diabetes medications' stability and how the products are supplied.

More work is need to determine the impact of weight loss programs in lowering blood sugar concentrations in type 2 diabetes.

Protease inhibitors can frequently lead to cardiovascular disease, diabetes, and obesity.

Researchers assess the monetary value for improved health status.

Darapladib can block Lp-PLA2, which can lead to diabetes-related vision loss.

Researchers evaluate the link between organ transplant and the increased likelihood of developing diabetes.

Approximately 24 to 25% of patients with type 2 diabetes and heart failure died within 18 months.

New data from the EMPA-REG OUTCOME trial showed the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance) significantly reduced the incidence of worsening kidney disease in type 2 diabetes patients.

Merck and Pfizer teamed up to create a new type 2 diabetes drug.

Anti-fetal brain autoantibodies shown to be specific to some mothers of children with autism.

Metformin has been found to reduce the need for insulin in diabetics.

Diabetic macular oedema could be reduced by the cardiovascular drug darapladib.

Follow-on biologic drug MK-1293 deemed non-inferior to insulin glargine (Lantus).

Seena Haines, PharmD, BCACP, FAPhA, BC-ADM, outlines how pharmacists can optimize their role in creating hospital discharge plans for diabetes patients.

Seena Haines, PharmD, BCACP, FAPhA, FASHP, BC-ADM, CDE, lists out factors that may contribute to the likelihood of a patient with diabetes needing to be readmitted.

Seena Haines, PharmD, BCACP, FAPhA, BC-ADM, discusses the types of goals pharmacists should discuss with patients with diabetes in order to avoid readmissions.

Treating type 2 diabetes with drugs and biologics that are most likely to be effective should be a health care priority.

Drug labels for canagliflozin and dapagliflozin revised to include acute injury warning.

Drug labels for canagliflozin and dapagliflozin revised to include acute injury warning.

Seena Haines, PharmD, BCACP, FAPhA, FASHP, BC-ADM, CDE, lists some factors that may contribute to the likelihood of a patient with diabetes needing to be readmitted.

Seena Haines, PharmD, BCACP, FAPhA, BC-ADM, outlines how pharmacists can optimize their role in creating hospital discharge plans for diabetes patients.

A natural compound could increase the overall health of patients with diabetes, heart disease, and obesity.

Health-system pharmacists should fill their patients with diabetes in on the benefits of shared medical appointments after hospital discharge.

Katie Traylor, a PGY2 pharmacy resident in ambulatory care and family medicine, outlines the major glucose monitoring counseling points pharmacists can offer to patients prior to discharge.